Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL6ST | P40189 | 7/20 | 1.00 |
| ▸ | STAT3 | P40763 | 1/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 2/20 | 0.34 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.33 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | PRKCA | P17252 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22261831 | 1.00 | IL6ST (1.00) | IL6STSTAT3PIK3CDNAAAPLA2G1B | |
| SCHEMBL11936832 | 0.79 | IL6ST (0.65) | IL6STSTAT3PIK3CDNAAAPLA2G1B | |
| SCHEMBL7413739 | 0.78 | IL6ST (0.65) | IL6STSTAT3PIK3CDNAAAPLA2G1B | |
| SCHEMBL8220018 | 0.78 | IL6ST (0.65) | IL6STSTAT3PIK3CDNAAAPLA2G1B | |
| SCHEMBL8211445 | 0.78 | IL6ST (0.65) | IL6STSTAT3PIK3CDNAAAPLA2G1B | |
| SCHEMBL8209630 | 0.78 | IL6ST (0.65) | IL6STSTAT3PIK3CDNAAAPLA2G1B | |
| SCHEMBL8211443 | 0.78 | IL6ST (0.65) | IL6STSTAT3PIK3CDNAAAPLA2G1B | |
| SCHEMBL8219403 | 0.78 | IL6ST (0.65) | IL6STSTAT3PIK3CDNAAAPLA2G1B | |
| SCHEMBL8209628 | 0.78 | IL6ST (0.65) | IL6STSTAT3PIK3CDNAAAPLA2G1B | |
| SCHEMBL31519438 | 0.78 | IL6ST (0.65) | IL6STSTAT3PIK3CDNAAAPLA2G1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260009081-A1 | CLONAL HEMATOPOIESIS AND CYTOKINE TARGETS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2026-01-08 | — | — | US | claimed |
| EP-3699174-B1 | COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME | ILAB (KR) | 2025-11-12 | — | — | EP | claimed |
| US-20200237728-A1 | CHEMOTHERAPEUTIC METHODS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2020-07-30 | — | — | US | claimed |
| US-20260131007-A1 | Mannose 6-Phosphate Receptor Binding Compounds for the Degradation of Extracellular Proteins | AVILAR THERAPEUTICS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260083851-A1 | POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2026-03-26 | — | — | US | disclosed |
| US-20260009081-A1 | CLONAL HEMATOPOIESIS AND CYTOKINE TARGETS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2026-01-08 | — | — | US | disclosed |
| EP-3699174-B1 | COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME | ILAB (KR) | 2025-11-12 | — | — | EP | disclosed |
| US-20250276061-A1 | METHOD AND COMPOSITION FOR INDUCING TOLERANCE | ZELARION MALTA LIMITED (MT) | 2025-09-04 | — | — | US | disclosed |
| US-20250223280-A1 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2025-07-10 | — | — | US | disclosed |
| US-12312340-B2 | Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteins | AVILAR THERAPEUTICS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| EP-4548916-A1 | IL-8 INHIBITORS FOR USE IN THE TREATMENT OF SOME SARCOMAS | Dompé farmaceutici SpA (IT) | 2025-05-07 | — | — | EP | disclosed |
| US-11452713-B2 | Chemotherapeutic methods for treating low-proliferative disseminated tumor cells | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-09-27 | — | — | US | disclosed |
| US-11439802-B2 | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract | BIORA THERAPEUTICS, INC. (US) | 2022-09-13 | — | — | US | disclosed |
| US-20220273196-A1 | INGESTIBLE DEVICE AND ASSOCIATED METHODS | GLAS USA LLC | 2022-09-01 | — | — | US | disclosed |
| US-20220249814-A1 | METHODS AND DEVICES FOR TREATING A DISEASE WITH BIOTHERAPEUTICS | GLAS USA LLC | 2022-08-11 | — | — | US | disclosed |
| EP-4015043-A1 | IMPROVED NK-BASED CELL THERAPY | ONK Therapeutics Limited (IE) | 2022-06-22 | — | — | EP | disclosed |
| EP-3982922-A1 | DISSACHARIDE FORMULATIONS FOR CONTROLLED DRUG RELEASE | Technical University of Denmark (DK) | 2022-04-20 | — | — | EP | disclosed |
| WO-2022047182-A1 | HIGH DOSE NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) PRECURSOR REGIMENS FOR REDUCTION OF INFLAMMATION IN HUMAN PATIENTS WITH PREEXISTING INFLAMMATION | UNIVERSITY OF WASHINGTON (US) | 2022-03-03 | — | — | WO | disclosed |
| US-20220025036-A1 | USE OF IL-1BETA BINDING ANTIBODIES | NOVARTIS AG (CH) | 2022-01-27 | — | — | US | disclosed |
| US-20200237728-A1 | CHEMOTHERAPEUTIC METHODS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2020-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12312340-B2 | Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteins | ASGR1, FCGR2A, FCGR3B | IL6ST 598/4885STAT3 4145/4885PIK3CD 3310/4885 |
| US-20260009081-A1 | CLONAL HEMATOPOIESIS AND CYTOKINE TARGETS | TET2, DNMT3A, IL36G | IL6ST 14/4885STAT3 23/4885PIK3CD 3313/4885 |
| US-20250223280-A1 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | ASGR1, FCGR2A, FCGR3B | IL6ST 598/4885STAT3 4145/4885PIK3CD 3310/4885 |
| US-20260083851-A1 | POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | ASGR1, FCGR2A, FCGR3B | IL6ST 39/4885STAT3 4238/4885PIK3CD 3883/4885 |
| US-20260131007-A1 | Mannose 6-Phosphate Receptor Binding Compounds for the Degradation of Extracellular Proteins | IGF2R, M6PR, MSR1 | IL6ST 33/4885STAT3 2903/4885PIK3CD 2930/4885 |
| US-20220025036-A1 | USE OF IL-1BETA BINDING ANTIBODIES | IL1B, IL1RN, IL1A | IL6ST 11/4885STAT3 231/4885PIK3CD 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.